166 related articles for article (PubMed ID: 38409373)
1. Neuroinflammation following anti-parkinsonian drugs in early Parkinson's disease: a longitudinal PET study.
Terada T; Bunai T; Hashizume T; Matsudaira T; Yokokura M; Takashima H; Konishi T; Obi T; Ouchi Y
Sci Rep; 2024 Feb; 14(1):4708. PubMed ID: 38409373
[TBL] [Abstract][Full Text] [Related]
2. Extrastriatal spreading of microglial activation in Parkinson's disease: a positron emission tomography study.
Terada T; Yokokura M; Yoshikawa E; Futatsubashi M; Kono S; Konishi T; Miyajima H; Hashizume T; Ouchi Y
Ann Nucl Med; 2016 Oct; 30(8):579-87. PubMed ID: 27299437
[TBL] [Abstract][Full Text] [Related]
3. Progression from unilateral to bilateral parkinsonism in early Parkinson disease: implication of mesocortical dopamine dysfunction by PET.
Yagi S; Yoshikawa E; Futatsubashi M; Yokokura M; Yoshihara Y; Torizuka T; Ouchi Y
J Nucl Med; 2010 Aug; 51(8):1250-7. PubMed ID: 20660377
[TBL] [Abstract][Full Text] [Related]
4. Quantification and discriminative power of
Delva A; Van Weehaeghe D; van Aalst J; Ceccarini J; Koole M; Baete K; Nuyts J; Vandenberghe W; Van Laere K
Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1913-1926. PubMed ID: 31776633
[TBL] [Abstract][Full Text] [Related]
5. Microglial activation and dopamine terminal loss in early Parkinson's disease.
Ouchi Y; Yoshikawa E; Sekine Y; Futatsubashi M; Kanno T; Ogusu T; Torizuka T
Ann Neurol; 2005 Feb; 57(2):168-75. PubMed ID: 15668962
[TBL] [Abstract][Full Text] [Related]
6. Neuroinflammation in the living brain of Parkinson's disease.
Ouchi Y; Yagi S; Yokokura M; Sakamoto M
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S200-4. PubMed ID: 20082990
[TBL] [Abstract][Full Text] [Related]
7. PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs.
Bang JI; Jung IS; Song YS; Park HS; Moon BS; Lee BC; Kim SE
Nucl Med Biol; 2016 Feb; 43(2):158-64. PubMed ID: 26872440
[TBL] [Abstract][Full Text] [Related]
8. Chronic exposure to dopamine agonists affects the integrity of striatal D
Politis M; Wilson H; Wu K; Brooks DJ; Piccini P
Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087
[TBL] [Abstract][Full Text] [Related]
9. GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.
Schneider JS; Cambi F; Gollomp SM; Kuwabara H; Brašić JR; Leiby B; Sendek S; Wong DF
J Neurol Sci; 2015 Sep; 356(1-2):118-23. PubMed ID: 26099170
[TBL] [Abstract][Full Text] [Related]
10. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.
Song IU; Chung YA; Oh JK; Chung SW
Acta Radiol; 2014 Apr; 55(3):366-71. PubMed ID: 23943629
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of Computed Tomography-Guided Methods for Spatial Normalization of Dopamine Transporter Positron Emission Tomography Image.
Kim JS; Cho H; Choi JY; Lee SH; Ryu YH; Lyoo CH; Lee MS
PLoS One; 2015; 10(7):e0132585. PubMed ID: 26147749
[TBL] [Abstract][Full Text] [Related]
12. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
Nurmi E; Ruottinen HM; Kaasinen V; Bergman J; Haaparanta M; Solin O; Rinne JO
Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547
[TBL] [Abstract][Full Text] [Related]
13. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Sakamoto M
Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
[TBL] [Abstract][Full Text] [Related]
14.
Takashima H; Terada T; Bunai T; Matsudaira T; Obi T; Ouchi Y
Front Neurol; 2022; 13():880407. PubMed ID: 35655619
[TBL] [Abstract][Full Text] [Related]
15. PET imaging of [
Varnäs K; Cselényi Z; Jucaite A; Halldin C; Svenningsson P; Farde L; Varrone A
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):367-375. PubMed ID: 30270409
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal DAT changes measured with [
Kerstens VS; Fazio P; Sundgren M; Brumberg J; Halldin C; Svenningsson P; Varrone A
Neuroimage Clin; 2023; 37():103347. PubMed ID: 36822016
[TBL] [Abstract][Full Text] [Related]
17. Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson's disease patients with impulse control disorders.
Navalpotro-Gomez I; Dacosta-Aguayo R; Molinet-Dronda F; Martin-Bastida A; Botas-Peñin A; Jimenez-Urbieta H; Delgado-Alvarado M; Gago B; Quiroga-Varela A; Rodriguez-Oroz MC
Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2065-2076. PubMed ID: 31273436
[TBL] [Abstract][Full Text] [Related]
18. In vivo direct relation of tau pathology with neuroinflammation in early Alzheimer's disease.
Terada T; Yokokura M; Obi T; Bunai T; Yoshikawa E; Ando I; Shimada H; Suhara T; Higuchi M; Ouchi Y
J Neurol; 2019 Sep; 266(9):2186-2196. PubMed ID: 31139959
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and influencing factors of
Kangli F; Hongguang Z; Yinghua L; Xiaoxiao D; Yuyin D; Lulu G; Yi L; Zhihui S; Ying Z
Front Neurol; 2023; 14():1195577. PubMed ID: 37483437
[TBL] [Abstract][Full Text] [Related]
20. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages.
Wang J; Zuo CT; Jiang YP; Guan YH; Chen ZP; Xiang JD; Yang LQ; Ding ZT; Wu JJ; Su HL
J Neurol; 2007 Feb; 254(2):185-90. PubMed ID: 17334953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
